Xencor Inc. Stock
Xencor Inc. Stock
The price for the Xencor Inc. stock decreased slightly today. Compared to yesterday there is a change of -€0.100 (-0.750%).
With 14 Buy predictions and only 2 Sell predictions the community sentiment for the stock is positive.
With a target price of 22 € there is a hugely positive potential of 65.41% for Xencor Inc. compared to the current price of 13.3 €.
Pros and Cons of Xencor Inc. in the next few years
Pros
?
G***** c******* t* c**********
?
W********* I********* f** t** n*** y****
?
C******** o* t** e**********
Cons
?
B****
?
S********** s********
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xencor Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xencor Inc. | -0.750% | -4.317% | -2.206% | -41.667% | -41.667% | -44.118% | -64.054% |
| Ironwood Pharmaceuticals | -0.740% | -9.459% | -4.965% | -37.383% | -36.190% | -76.716% | -72.653% |
| Novocure Ltd | -2.280% | 7.340% | 8.635% | -61.544% | -61.332% | -84.916% | -91.963% |
| Iovance Biotherapeutics Inc. | -0.280% | 11.832% | 10.644% | -66.564% | -65.306% | -57.442% | -94.118% |
Comments
Xencor (NASDAQ:XNCR) is now covered by analysts at Truist Financial Corporation. They set a "buy" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its "outperform" rating reaffirmed by analysts at Wedbush. They now have a $26.00 price target on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
Xencor (NASDAQ:XNCR) had its price target raised by analysts at Royal Bank Of Canada from $18.00 to $19.00. They now have an "outperform" rating on the stock.
Show more
Ratings data for XNCR provided by MarketBeat
News
Xencor (XNCR) Q2 Revenue Jumps 82%
Xencor (NASDAQ:XNCR), a clinical-stage biopharmaceutical company focused on engineered antibodies for serious diseases, reported second quarter 2025 results on August 6, 2025. The company’s GAAP
